谷歌浏览器插件

订阅小程序

在清言上使用

立即登录

学术主页个人账号

我的关注论文收藏浏览历史

AML-197 QuANTUM-First Trial: FMS-like Tyrosine Kinase 3-Internal Tandem Duplication (Flt3-Itd)–specific Measurable Residual Disease (MRD) Clearance Assessed Through Induction and Consolidation is Associated with Improved Overall Survival (OS) in Newly Diagnosed (ND) FLT3-ITD+ AML Patients

Alexander E. Perl,Harry P. Erba,Pau Montesinos,Radovan Vrhovac,Elżbieta Patkowska,Hee-Je Kim,Pavel Zak,Po-Nan Wang,Jaime E. Connolly Rohrbach, Ken, Li Liu,Yasser Mostafa Kamel, Karima Imadalou,Arnaud Lesegretain,Jorge Cortes,Mikkael A. Sekeres,Hervé Dombret,Sergio Amadori,Jianxiang Wang,Richard F. Schlenk

Clinical Lymphoma Myeloma & Leukemia（2024）

引用 0|浏览1

关键词

AML,FLT3-ITD+,MRD,quizartinib,clinical trial,phase 3

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要